Functional repair of p53 mutation in colorectal cancer cells using trans-splicing

Oncotarget

Volumn 6, Issue 4, 2015, Pages 2034-2045

  He, Xingxing ^a   Liao, Jiazhi ^a   Liu, Fang ^a   Yan, Junwei ^a   Yan, Jingjun ^a   Shang, Haitao ^a   Dou, Qian ^a   Chang, Ying ^a   Lin, Jusheng ^a   Song, Yuhu ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Colorectal cancer cells; Mutant p53; Trans splicing

Indexed keywords

ADENOVIRUS VECTOR; PROTEIN P53;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER GROWTH; CELL PROLIFERATION; COLORECTAL CANCER; CONTROLLED STUDY; G1 PHASE CELL CYCLE CHECKPOINT; GENE CASSETTE; GENE INDUCTION; GENE MUTATION; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; HT 29 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; P53 GENE; TRANS SPLICING; TUMOR XENOGRAFT; ADENOVIRIDAE; ANIMAL; BAGG ALBINO MOUSE; CELL CYCLE CHECKPOINT; COLORECTAL NEOPLASMS; DRUG SCREENING; GENE THERAPY; GENE VECTOR; GENETIC COMPLEMENTATION; GENETICS; METABOLISM; MUTATION; NUDE MOUSE; PROCEDURES; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE; TUMOR VOLUME; WESTERN BLOTTING;

ADENOVIRIDAE; ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; GENETIC COMPLEMENTATION TEST; GENETIC THERAPY; GENETIC VECTORS; HT29 CELLS; HUMANS; MICE, INBRED BALB C; MICE, NUDE; MUTATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANS-SPLICING; TUMOR BURDEN; TUMOR SUPPRESSOR PROTEIN P53; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84922983014     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2988     Document Type: Article

References (42)

1. Hainaut P and Wiman KG. 30 years and a long way into p53 research. Lancet Oncol. 2009; 10:913-919.
2. Kruse JP and Gu W. Modes of p53 regulation. Cell. 2009; 137:609-622.
3. Oren M and Rotter V. Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect Biol. 2010; 2:a001107.
4. Weisz L, Oren M and Rotter V. Transcription regulation by mutant p53. Oncogene. 2007; 26:2202-2211.
5. Blagosklonny MV, Trostel S, Kayastha G, Demidenko ZN, Vassilev LT, Romanova LY, Bates S and Fojo T. Depletion of mutant p53 and cytotoxicity of histone deacetylase inhibitors. Cancer Res. 2005; 65:7386-7392.
6. Yu X, Blanden AR, Narayanan S, Jayakumar L, Lubin D, Augeri D, Kimball SD, Loh SN and Carpizo DR. Small molecule restoration of wildtype structure and function of mutant p53 using a novel zinc-metallochaperone based mechanism. Oncotarget. 2014; 5:8879-8892.
7. Tang X, Zhu Y, Han L, Kim AL, Kopelovich L, Bickers DR and Athar M. CP-31398 restores mutant p53 tumor suppressor function and inhibits UVB-induced skin carcinogenesis in mice. J Clin Invest. 2007; 117:3753-3764.
8. Yu X, Vazquez A, Levine AJ and Carpizo DR. Allele-specific p53 mutant reactivation. Cancer cell. 2012; 21:614-625.
9. Lane DP, Cheok CF and Lain S. p53-based cancer therapy. Cold Spring Harb Perspect Biol. 2010; 2:a001222.
10. Cheok CF, Verma CS, Baselga J and Lane DP. Translating p53 into the clinic. Nature reviews Clinical oncology. 2011; 8:25-37.
11. Shimada H, Matsubara H, Shiratori T, Shimizu T, Miyazaki S, Okazumi S, Nabeya Y, Shuto K, Hayashi H, Tanizawa T, Nakatani Y, Nakasa H, Kitada M, et al. Phase I/II adenoviral p53 gene therapy for chemoradiation resistant advanced esophageal squamous cell carcinoma. Cancer science. 2006; 97:554-561.
12. Guo J and Xin H. Chinese gene therapy. Splicing out the West? Science. 2006; 314:1232-1235.
13. Roth JA, Nguyen D, Lawrence DD, Kemp BL, Carrasco CH, Ferson DZ, Hong WK, Komaki R, Lee JJ, Nesbitt JC, Pisters KM, Putnam JB, Schea R, et al. Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer. Nat Med. 1996; 2:985-991.
14. Donehower LA and Lozano G. 20 years studying p53 functions in genetically engineered mice. Nature reviews Cancer. 2009; 9:831-841.
15. Foulkes WD. p53-master and commander. N Engl J Med. 2007; 357:2539-2541.
16. Kong XJ, Song YH, Lin JS, Huang HJ, Wang NX, Liu NZ, Li B and Jin YX. Maxizyme-mediated specific inhibition on mutant-type p53 in vitro. World J Gastroenterol. 2003; 9:1571-1575.
17. Cai DW, Mukhopadhyay T and Roth JA. Suppression of lung cancer cell growth by ribozyme-mediated modification of p53 pre-mRNA. Cancer gene therapy. 1995; 2:199-205.
18. Bossi G, Marampon F, Maor-Aloni R, Zani B, Rotter V, Oren M, Strano S, Blandino G and Sacchi A. Conditional RNA interference in vivo to study mutant p53 oncogenic gain of function on tumor malignancy. Cell Cycle. 2008; 7:1870-1879.
19. Bossi G, Lapi E, Strano S, Rinaldo C, Blandino G and Sacchi A. Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression. Oncogene. 2006; 25:304-309.
20. Lozano G. Mouse models of p53 functions. Cold Spring Harb Perspect Biol. 2010; 2:a001115.
21. Wood M, Yin H and McClorey G. Modulating the expression of disease genes with RNA-based therapy. PLoS Genet. 2007; 3:e109.
22. O'Connor TP and Crystal RG. Genetic medicines: treatment strategies for hereditary disorders. Nat Rev Genet. 2006; 7:261-276.
23. Yang Y and Walsh CE. Spliceosome-mediated RNA trans-splicing. Mol Ther. 2005; 12:1006-1012.
24. Mansfield SG, Kole J, Puttaraju M, Yang CC, Garcia-Blanco MA, Cohn JA and Mitchell LG. Repair of CFTR mRNA by spliceosome-mediated RNA trans-splicing. Gene Ther. 2000; 7:1885-1895.
25. Liu X, Jiang Q, Mansfield SG, Puttaraju M, Zhang Y, Zhou W, Cohn JA, Garcia-Blanco MA, Mitchell LG and Engelhardt JF. Partial correction of endogenous DeltaF508 CFTR in human cystic fibrosis airway epithelia by spliceosome-mediated RNA trans-splicing. Nat Biotechnol. 2002; 20:47-52.
26. Liu X, Luo M, Zhang LN, Yan Z, Zak R, Ding W, Mansfield SG, Mitchell LG and Engelhardt JF. Spliceosome-mediated RNA trans-splicing with recombinant adeno-associated virus partially restores cystic fibrosis transmembrane conductance regulator function to polarized human cystic fibrosis airway epithelial cells. Hum Gene Ther. 2005; 16:1116-1123.
27. Chao H, Mansfield SG, Bartel RC, Hiriyanna S, Mitchell LG, Garcia-Blanco MA and Walsh CE. Phenotype correction of hemophilia A mice by spliceosome-mediated RNA trans-splicing. Nat Med. 2003; 9:1015-1019.
28. Tahara M, Pergolizzi RG, Kobayashi H, Krause A, Luettich K, Lesser ML and Crystal RG. Trans-splicing repair of CD40 ligand deficiency results in naturally regulated correction of a mouse model of hyper-IgM X-linked immunodeficiency. Nat Med. 2004; 10:835-841.
29. Fearon ER. Molecular genetics of colorectal cancer. Annu Rev Pathol. 2011; 6:479-507.
30. Goh AM, Coffill CR and Lane DP. The role of mutant p53 in human cancer. The Journal of pathology. 2011; 223:116-126.
31. Freed-Pastor WA and Prives C. Mutant p53: one name, many proteins. Genes & development. 2012; 26:1268-1286.
32. Fujiwara T, Cai DW, Georges RN, Mukhopadhyay T, Grimm EA and Roth JA. Therapeutic effect of a retroviral wild-type p53 expression vector in an orthotopic lung cancer model. Journal of the National Cancer Institute. 1994; 86:1458-1462.
33. Bossi G, Mazzaro G, Porrello A, Crescenzi M, Soddu S and Sacchi A. Wild-type p53 gene transfer is not detrimental to normal cells in vivo: implications for tumor gene therapy. Oncogene. 2004; 23:418-425.
34. Wang Y, Suh YA, Fuller MY, Jackson JG, Xiong S, Terzian T, Quintas-Cardama A, Bankson JA, El-Naggar AK and Lozano G. Restoring expression of wild-type p53 suppresses tumor growth but does not cause tumor regression in mice with a p53 missense mutation. J Clin Invest. 2011; 121:893-904.
35. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D. Global cancer statistics. CA: a cancer journal for clinicians. 2011; 61:69-90.
36. Rodrigues NR, Rowan A, Smith ME, Kerr IB, Bodmer WF, Gannon JV and Lane DP. p53 mutations in colorectal cancer. Proc Natl Acad SciUSA. 1990; 87:7555-7559.
37. Liu Y and Bodmer WF. Analysis of P53 mutations and their expression in 56 colorectal cancer cell lines. Proc Natl Acad SciUSA. 2006; 103:976-981.
38. Puttaraju M, DiPasquale J, Baker CC, Mitchell LG and Garcia-Blanco MA. Messenger RNA repair and restoration of protein function by spliceosome-mediated RNA trans-splicing. Mol Ther. 2001; 4:105-114.
39. Song Y, Lou HH, Boyer JL, Limberis MP, Vandenberghe LH, Hackett NR, Leopold PL, Wilson JM and Crystal RG. Functional cystic fibrosis transmembrane conductance regulator expression in cystic fibrosis airway epithelial cells by AAV6.2-mediated segmental trans-splicing. Hum Gene Ther. 2009; 20:267-281.
40. He XX, Chang Y, Meng FY, Wang MY, Xie QH, Tang F, Li PY, Song YH and Lin JS. MicroRNA-375 targets AEG-1 in hepatocellular carcinoma and suppresses liver cancer cell growth in vitro and in vivo. Oncogene. 2012; 31:3357-3369.
41. Wang Z, Liu F, Tu W, Chang Y, Yao J, Wu W, Jiang X, He X, Lin J and Song Y. Embryonic liver fodrin involved in hepatic stellate cell activation and formation of regenerative nodule in liver cirrhosis. Journal of cellular and molecular medicine. 2012; 16:118-128.
42. Wang Z, Song Y, Tu W, He X, Lin J and Liu F. beta-2 spectrin is involved in hepatocyte proliferation through the interaction of TGFbeta/Smad and PI3K/AKT signalling. Liver international: official journal of the International Association for the Study of the Liver. 2012; 32:1103-1111.